Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

NCT03486938 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment
Prodromal Alzheimer's Disease

Interventions

DRUG: Placebo Oral Tablet
DRUG: AGB101 220 mg tablet

Sponsor

AgeneBio

Collaborators

[object Object]